List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cryptococcosis - Overview
Cryptococcosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptococcosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptococcosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
Amtixbio Co Ltd
Basilea Pharmaceutica Ltd
Collaborations Pharmaceuticals Inc
iNtRON Biotechnology Inc
Mycovia Pharmaceuticals Inc
Novabiotics Ltd
Pulmocide Ltd
Visterra Inc
Cryptococcosis - Drug Profiles
Drugs for Cryptococcosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosmanogepix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iNEYD-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
isavuconazonium sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PC-1244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Cryptococcosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-FNG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cryptococcosis - Dormant Projects
Cryptococcosis - Discontinued Products
Cryptococcosis - Product Development Milestones
Featured News & Press Releases
Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications
Feb 11, 2019: FDA grants orphan drug designation to Amplyx Pharmaceuticals for APX001 for treatment of cryptococcosis
Apr 18, 2018: Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
Mar 12, 2018: Amplyx Pharmaceuticals Receives Fourth Qualified Infectious Disease Product Designation from the FDA for APX001
Jun 27, 2016: New Promise Against Deadly Global Fungal Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cryptococcosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cryptococcosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2020
Cryptococcosis - Pipeline by Amtixbio Co Ltd, H1 2020
Cryptococcosis - Pipeline by Basilea Pharmaceutica Ltd, H1 2020
Cryptococcosis - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020
Cryptococcosis - Pipeline by iNtRON Biotechnology Inc, H1 2020
Cryptococcosis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Cryptococcosis - Pipeline by Novabiotics Ltd, H1 2020
Cryptococcosis - Pipeline by Pulmocide Ltd, H1 2020
Cryptococcosis - Pipeline by Visterra Inc, H1 2020
Cryptococcosis - Dormant Projects, H1 2020
Cryptococcosis - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Cryptococcosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned
• Amplyx Pharmaceuticals Inc
• Amtixbio Co Ltd
• Basilea Pharmaceutica Ltd
• Collaborations Pharmaceuticals Inc
• iNtRON Biotechnology Inc
• Mycovia Pharmaceuticals Inc
• Novabiotics Ltd
• Pulmocide Ltd
• Visterra Inc